Landos Biopharma, Inc. (LABP): Price and Financial Metrics
LABP Price/Volume Stats
| Current price | $3.84 | 52-week high | $7.57 |
| Prev. close | $3.85 | 52-week low | $2.11 |
| Day low | $3.53 | Volume | 8,405 |
| Day high | $3.88 | Avg. volume | 23,777 |
| 50-day MA | $3.88 | Dividend yield | N/A |
| 200-day MA | $3.58 | Market Cap | 11.97M |
LABP Stock Price Chart Interactive Chart >
Landos Biopharma, Inc. (LABP) Company Bio
Landos Biopharma, Inc. operates as a pharmaceutical company. The Company discovers and develops oral therapeutics for patients with autoimmune diseases. Landos Biopharma serves customers worldwide.
Latest LABP News From Around the Web
Below are the latest news stories about LANDOS BIOPHARMA INC that investors may wish to consider to help them evaluate LABP as an investment opportunity.
Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressNX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial is Ongoing; Top-line Readout Expected in Q4 2024 NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced presentation of new data on the rapi |
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial CellsCollaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid ModelsNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a strategic research collaboration to investigate the effects of NX-13 on epithelial cells with the Inflammatory Bowel Disease (IBD) Team at KU Leuven and University Hospital |
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsInitiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June |
Landos Biopharma to Present at the 2023 Jefferies Healthcare ConferenceNEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY. Gregory Oakes, Chief Executive Officer, and Fabio Cataldi, Chief Medical Officer, will provide a corporate update, including highlights of the NX-13 program and the recent la |
Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. “Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board,” said Gregory Oakes, President and CEO of Landos. “Dr. Batycky has a proven track record, and we |
LABP Price Returns
| 1-mo | 3.50% |
| 3-mo | 11.47% |
| 6-mo | 37.00% |
| 1-year | -42.97% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -23.22% |
| 2022 | -89.58% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...